### Day 1 - Nov. 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 – 3:15pm</td>
<td>Welcome</td>
</tr>
</tbody>
</table>
| 3:15 – 4:45pm | **Rapid Fire Sessions** – Review of BioCon findings presented by BioCon investigators. What’s been found? What does it mean? Where does it lead?  
- Metabolomics (including pediatrics)  
  Michelle Denburg, MD, MSCE  
- Proteomics  
  Rajat Deo, MD, MTR  
- Targeted Markers (including pediatrics)  
  Michael Shlipak, MD, MPH |
| 4:45 – 5:00 pm | Break                                                                 |
| 5:00 – 7:00pm | Networking and poster session (Peacock Spring)  
- Informational posters describing BioCon data resources, and research posters on CKD biomarkers  
- Hors d’oeuvres and cash bar |

### Day 2 - Nov. 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Item</th>
</tr>
</thead>
</table>
| 8:30 – 9:30 am | 1:1 mentoring sessions with BioCon Investigators (Coral Spring and Manatee Spring I)  
(15-20 min blocks) / Breakfast |
| 9:30 – 10:30 am | **CKD Biomarkers and the -omics world**  
Morgan Grams MD, PhD; Eugene Rhee, MD; Ruth Dubin, MD |
| 10:30 – 10:45 am | Break                                                                 |
| 10:45 – 11:30 am | **How to get involved with BioCon Data**  
Michelle Denburg, MD, MSCE; Joachim Ix, MD  
- How to get data access and best share resources  
- Opportunities for research and writing using BioCon data  
- Panel of early stage investigators who have used BioCon data and lessons learned |
| 11:30 – 12:45 pm | Lunch break (attendees to have lunch on their own) |
| 12:45 – 1:30 pm | **Lessons Learned from Central Lab**  
Joseph Bonventre, MD, PhD  
what to look out for in biomarker research; things to be aware of; issues that arise in biomarker assays  
- 15 minute Q&A |
| 1:30 – 3:30 pm | **Biomarker Think Tank** – Panelists will discuss their perspectives on CKD biomarker research and future directions in the field (~10 minutes per panelist), followed by moderator led discussion  
Panel participants:  
Nicholas King, MS  
Critical Path Institute  
Stefan Sultana, MD  
AstraZeneca  
Aliza Thompson, MD  
U.S. Food and Drug Administration  
Frank Dieterle, PhD  
Novartis  
Paul Conway  
American Association of Kidney Patients  
Katherine T Landschulz, PhD  
Labcorp Drug Development |
| 3:30 pm | Adjourn                                                               |